使用CRISPR/Cas9屏幕进行SOCS1编辑的瘤透淋巴细胞治疗的合理设计
The Journal of clinical investigation
|December 15, 2023
概括
科学家们使用CRISPR屏幕寻找改善T细胞疗法的点. 他们确定SOCS1是增强抗瘤活性的关键基因,导致一种名为KSQ-001.1.的新工程疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 基因编辑 基因编辑
- 癌症治疗治疗 癌症治疗
背景情况:
- 瘤透淋巴细胞 (TIL) 疗法在耐火实体瘤中显示出前景.
- 提高TIL治疗的反应率和持续时间至关重要.
- 需要确定新的点来增强T细胞介导的抗瘤活性.
研究的目的:
- 通过大规模CRISPR屏幕识别可以增强T细胞治疗疗效的基因.
- 研究SOCS1在调节T细胞耗尽和功能中的作用.
- 开发一种具有增强抗瘤活性的工程TIL疗法.
主要方法:
- 在体外和体内进行的定期间隔的短时间palindromic重复 (CRISPR) /Cas9查以确定T细胞增强标.
- 利用小鼠CD8+T细胞治疗模型研究SOCS1功能.
- 进行了SOCS1编码区域的全面CRISPR屏,以确定最佳sgRNAs.
- 制造的KSQ-001是一种工程TIL疗法,使用CRISPR/Cas9介导的SOCS1失活.
主要成果:
- SOCS1被确定为一个顶级的T细胞增强点.
- SOCS1作为一个关键的检查点,抑制T细胞的积累和瘤的耗尽.
- 针对SOCS1 SH2域的sgRNA是最有效的.
- 在小鼠模型中,KSQ-001表现出对细胞因子信号的反应能力增加,并增强了体内抗瘤功能.
结论:
- 克里斯普尔/Cas9屏幕对于合理设计T细胞疗法的有效.
- 不激活SOCS1可以增强TIL治疗的抗瘤活性.
- 使用SOCS1无活化的工程TIL疗法代表了癌症治疗的有希望的策略.
相关概念视频
01:59CRISPR
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
01:28CRISPR/Cas9 Genome Editing
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...